Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Shares Issued (2022 - 2025)

BioXcel Therapeutics has reported Shares Issued over the past 4 years, most recently at $5.8 million for Q4 2025.

  • Quarterly results put Shares Issued at $5.8 million for Q4 2025, down 17.7% from a year ago — trailing twelve months through Dec 2025 was $58.1 million (up 47.12% YoY), and the annual figure for FY2025 was $58.1 million, up 46.5%.
  • Shares Issued for Q4 2025 was $5.8 million at BioXcel Therapeutics, down from $38.2 million in the prior quarter.
  • Over the last five years, Shares Issued for BTAI hit a ceiling of $38.2 million in Q3 2025 and a floor of -$24.1 million in Q4 2023.
  • Median Shares Issued over the past 4 years was $5.3 million (2024), compared with a mean of $7.6 million.
  • Biggest five-year swings in Shares Issued: crashed 48398.0% in 2023 and later soared 10265.5% in 2024.
  • BioXcel Therapeutics' Shares Issued stood at $50000.0 in 2022, then crashed by 48398.0% to -$24.1 million in 2023, then soared by 128.99% to $7.0 million in 2024, then dropped by 17.7% to $5.8 million in 2025.
  • The last three reported values for Shares Issued were $5.8 million (Q4 2025), $38.2 million (Q3 2025), and $140000.0 (Q2 2025) per Business Quant data.